Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2842213 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-6-phosphofructo-2-Kinase/fructose-2,6-Biphosphatase 3 (PFKFB3) (AA 454-484), (C-Term) antibody
- Antibody type
- Polyclonal
- Description
- This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 454-484, C-Term
- Antibody clone number
- RB04030
- Vial size
- 80 μL
- Storage
- Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots.
- Handling
- Avoid freeze-thaw cycles.
Submitted references Insulin-independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice.
Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3.
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.
Yamasaki K, Hayashi Y, Okamoto S, Osanai M, Lee GH
Cancer science 2010 Jan;101(1):65-72
Cancer science 2010 Jan;101(1):65-72
Interleukin 6 enhances glycolysis through expression of the glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3.
Ando M, Uehara I, Kogure K, Asano Y, Nakajima W, Abe Y, Kawauchi K, Tanaka N
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2010 Apr;77(2):97-105
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2010 Apr;77(2):97-105
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.
Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J
Molecular cancer therapeutics 2008 Jan;7(1):110-20
Molecular cancer therapeutics 2008 Jan;7(1):110-20
Ras transformation requires metabolic control by 6-phosphofructo-2-kinase.
Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J
Oncogene 2006 Nov 23;25(55):7225-34
Oncogene 2006 Nov 23;25(55):7225-34
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC